Isoprene has three key small molecule assets in development at clinical and preclinical stages. Two assets are orally available non-Cereblon molecular glue degraders for multiple oncology indications including Prostate Cancer - AR, AR-V7, and Mnk1/2, breast cancer, TNBC and PDAC. In vivo data with all our optimized molecules/development candidates demonstrates tumor regression. Our first in class development candidate D7 prevents translation of oncogenic proteins by degrading Mnk1/2 and AR. Isoprene firmly expects D7 to be successful as a stand alone and a combination therapy in overcoming intrinsic and extrinsic cancer resistance in multiple solid and blood tumors. Isoprene has a Phase 2 Clinical asset for PDAC which has met its primary endpoint of radiographic response in combination with Gemcitabine. It has optimized this asset. Two of Isoprene's assets are funded with a total of $4 million in SBIRs